Cabot (CBT) Q3 Earnings Surpass Estimates

Core Insights - Cabot (CBT) reported quarterly earnings of $1.9 per share, exceeding the Zacks Consensus Estimate of $1.8 per share, but down from $1.92 per share a year ago, indicating a slight year-over-year decline [1] - The company posted revenues of $923 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.09% and down from $1.02 billion year-over-year [2] - Cabot shares have declined approximately 21.2% year-to-date, contrasting with the S&P 500's gain of 6.1% [3] Earnings Performance - Over the last four quarters, Cabot has surpassed consensus EPS estimates two times [2] - The recent earnings surprise of +5.56% indicates a positive deviation from expectations, while the previous quarter's surprise was +2.15% [1][2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.79, with projected revenues of $984.79 million, and for the current fiscal year, the EPS estimate is $7.25 on revenues of $3.83 billion [7] - The estimate revisions trend for Cabot was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6] Industry Context - The Chemical - Diversified industry, to which Cabot belongs, is currently ranked in the bottom 6% of over 250 Zacks industries, indicating a challenging environment [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Cabot's stock performance [5]